Quantitative Structure-Property Relationships Modeling to Predict in Vitro and in Vivo Binding of Drugs to the Bile Sequestrant, Colesevelam (Welchol)

Journal of Clinical Pharmacology

Volumn 49, Issue 10, 2009, Pages 1185-1195

  Walker, Joseph R ^a   Brown, Karen ^a   Rohatagi, Shashank ^a   Bathala, Mohinder S ^a   Xu, Chao ^b   Wickremasingha, Prachi K ^a   Salazar, Daniel E ^a   Mager, Donald E ^b  

^a DAIICHI SANKYO INC   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Drug drug interactions; In vitro drug interaction; Lipophilicity; Mathematical modeling; Molecular modeling

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; CEFALEXIN; CIPROFLOXACIN; CLOFIBRATE; COLESEVELAM; COLESTYRAMINE; DIGOXIN; ENALAPRIL; ETHINYLESTRADIOL; FENOFIBRATE; GLIBENCLAMIDE; GLIPIZIDE; LEVOTHYROXINE; METFORMIN; METOPROLOL; MEVINOLIN; NIFEDIPINE; NORETHISTERONE; OLMESARTAN; PHENYTOIN; PIOGLITAZONE; QUINIDINE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG SOLUBILITY; HUMAN; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; MATHEMATICAL MODEL; MOLECULAR MODEL; PARTIAL LEAST SQUARES REGRESSION; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; UNIVARIATE ANALYSIS;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHOLESTYRAMINE RESIN; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, MOLECULAR; PRESCRIPTION DRUGS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70349515826     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009340783     Document Type: Article

References (38)

1. Staels B., Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 2007 ; 67: 1383-1392.
2. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL Results of the glucose-lowering effect of Welchol study (glows): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther. 2007 ; 29: 74-83.
3. Bays HE, Goldberg RB, Truitt KE, Jones MR Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008 ; 168: 1975-1983.
4. Fonseca VA, Rosenstock J., Wang AC, Truitt KE, Jones MR Colesevelam HCL improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008 ; 31: 1479-1484.
5. Goldberg RB, Fonseca VA, Truitt KE, Jones MR Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008 ; 168: 1531-1540.
6. Bays H., Dujovne C. Colesevelam HCL: a non-systemic lipid-altering drug. Expert Opin Pharmacother. 2003 ; 4: 779-790.
7. Davidson MH, Dillon MA, Gordon B., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 ; 159: 1893-1900.
8. Heller DP, Burke SK, Davidson DM, Donovan JM Absorption of colesevelamhydrochloride in healthy volunteers. Ann Pharmacother. 2002 ; 36: 398-403.
9. Aldridge MA, Ito MK Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother. 2001 ; 35: 898-907.
10. Grundy SM, Ahrens EH Jr, Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 1971 ; 78: 94-121.
11. Shepherd J., Packard CJ, Bicker S., Lawrie TD, Morgan HG Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med. 1980 ; 302: 1219-1222.
12. Davidson MH, Toth P., Weiss S., et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001 ; 24: 467-474.
13. Hunninghake D., Insull W. Jr, Toth P., et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001 ; 158: 407-416.
14. Knapp HH, Schrott H., Ma P., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001 ; 110: 352-360. (Pubitemid 32248724)
15. Bays HE, Dujovne CA Drug interactions of lipid-altering drugs. Drug Saf. 1998 ; 19: 355-371.
16. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother. 2002 ; 36: 392-397.
17. Donovan JM, Stypinski D., Stiles MR, Olson TA, Burke SK Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther. 2000 ; 14: 681-690.
18. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCL on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet. 2004 ; 43: 943-950.
19. Mager DE, Jusko WJ Quantitative structure-pharmacokinetic/ pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2002 ; 91: 2441-2451.
20. Meylan WM, Howard PH Atom/fragment contribution method for estimating octanol-water partition coefficients. J Pharm Sci. 1995 ; 84: 83-92.
21. Smith DA, van de Waterbeemd H., Walker DK Pharmacokinetics and Metabolism in Drug Design. New York: Wiley-VCH ; 2001.
22. Scifinder. Columbus, OH: Chemical Abstracts Service; 2006.
23. Mager DE Quantitative structure-pharmacokinetic/pharmacodynamic relationships. Adv Drug Deliv Rev. 2006 ; 58: 1326-1356.
24. Van der Graaf PH, Nilsson J., Van Schaick EA, Danhof M. Multivariate quantitative structure-pharmacokinetic relationships (QSPKR) analysis of adenosine a1 receptor agonists in rat. J Pharm Sci. 1999 ; 88: 306-312.
25. Geladi P., Kowalski B. Partial least-squares regression: a tutorial. Anal Chim Acta. 1986 ; 185: 1-17.
26. Mayer JM, van de Waterbeemd H. Development of quantitative structure-pharmacokinetic relationships. Environ Health Perspect. 1985 ; 61: 295-306.
27. Seydel JK, Schaper KJ Quantitative structure-pharmacokinetic relationships and drug design. Pharmacol Ther. 1981 ; 15: 131-182.
28. Topliss JG Quantitative Structure-Activity Relationships of Drugs. New York: Academic Press ; 1983.
29. Colmenarejo G., Alvarez-Pedraglio A., Lavandera JL Cheminformatic models to predict binding affinities to human serum albumin. J Med Chem. 2001 ; 44: 4370-4378.
30. Turner JV, Maddalena DJ, Cutler DJ Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int J Pharm. 2004 ; 270: 209-219.
31. Yamazaki K., Kanaoka M. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J Pharm Sci. 2004 ; 93: 1480-1494.
32. Fliszar KA, Hill BT, Foster N. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. J Pharm Sci. 2007 ; 96: 2161-2170.
33. Usansky HH, Sinko PJ Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and f(a). J Pharmacol Exp Ther. 2005 ; 314: 391-399.
34. Bailey DN, Coffee JJ, Anderson B., Manoguerra AS Interaction of tricyclic antidepressants with cholestyramine in vitro. Ther Drug Monit. 1992 ; 14: 339-342.
35. Brown DD, Schmid J., Long RA, Hull JH A steady-state evaluation of the effects of propantheline bromide and cholestyramine on the bioavailability of digoxin when administered as tablets or capsules. J Clin Pharmacol. 1985 ; 25: 360-364.
36. Malloy MJ, Ravis WR, Pennell AT, Diskin CJ Effect of cholestyramine resin on single dose valproate pharmacokinetics. Int J Clin Pharmacol Ther. 1996 ; 34: 208-211.
37. Jahnchen E., Meinertz T., Gilfrich HJ, Kersting F., Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. Br J Clin Pharmacol. 1978 ; 5: 437-440.
38. Callaghan JT, Tsuru M., Holtzman JL, Hunninghake DB Effect of cholestyramine and colestipol on the absorption of phenytoin. Eur J Clin Pharmacol. 1983 ; 24: 675-678.